Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

Completed · Phase 2 · Has a placebo group

Conditions studied: Contrast-Induced Acute Kidney Injury

In brief

The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.

Key facts

Study ID
NCT01146925
Run by
CorMedix Therapeutics
People needed
60
Starts
2010-06-01
Expected to finish
2011-06-01
Last updated by the study team
2011-06-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.